^{Panasonic acquires Bayer diabetes care business for €1bn}

Panasonic Healthcare Holdings completed the acquisition of German diabetes care business Bayer for JPY132bn (€1bn).

The companies entered a definitive agreement for the business in June 2015.

The new standalone Diabetes Care business, which is named Ascensia Diabetes Care Holdings with headquarters in Basel, Switzerland, will provide enhanced solutions and precision tools to treat people with diabetes.

^{K2M Group’s next-generation Rhine cervical disc system gets CE Mark}

US-based K2M Group Holdings received CE Mark approval for its next-generation Rhine cervical disc system to market in Europe and other countries.

The company has developed the next-generation cervical artificial disc replacement for the treatment of degenerative disc disease.

The system features one-piece compressible polymer core design with dome-shaped, plasma-coated endplates and central-split keel.

^{Boston launches LithoVue digital flexible ureteroscope in US and Europe}

US-based medical device manufacturer Boston Scientific launched the LithoVue single-use digital flexible ureteroscope in the US and Europe.

The LithoVue system is designed to carry out minimally invasive endoscopic procedures to diagnose and treat stones and other conditions of the kidney, ureter and bladder.

The system offers a single-use flexible ureteroscope for urologists, and is designed to address the inconsistent performance, operational challenges and costs associated with widely used reusable scopes that require maintenance, sterilisation and reprocessing.

^{PerkinElmer acquires Swedish DNA analysis firm Vanadis Diagnostics}

US-based firm PerkinElmer completed the acquisition of Sweden-based DNA analysis firm Vanadis Diagnostics for an undisclosed amount.

The Swedish firm is developing a new solution for non-invasive prenatal testing (NIPT) based on digital analysis of cell-free DNA.

With the acquisition complete, PerkinElmer will be able to use the Vanadis platform to provide a cost-effective and high-throughput approach to NIPT, helping to provide wider access for pregnant women.

^{Philips and Sijunjung Regency to offer new telehealth service in Indonesia}

Royal Philips entered an agreement with Indonesian Sijunjung Regency to provide its new telehealth service, mobile obstetrics monitoring (MOM), in the West Sumatra region.

The company has designed the smartphone-based digital health service to identify mothers-to-be at high-risk of pregnancy-related complications, helping reduce maternal mortality rates.

In order to deploy the digital solution effectively in the region, Philip is working with Indonesia telecommunication provider PT TELKOM.

^{Boston Scientific and Accenture develop new digital health solution for chronic cardiovascular diseases}

US-based medical device firm Boston Scientific, along with Accenture, has developed a new cloud-based and data-driven digital health solution, Advantics Care Pathway Transformation, to help improve patient outcomes and reduce costs.

The new solution has been designed to be used in hospitals to treat patients with chronic cardiovascular diseases.

The Advantics solution will allow providers to make more proactive and informed decisions based on insights into the patient population in order to improve the care a patient experiences from hospital stay through post-discharge care and in-home support.

^{Panasonic and Kyoto develop new remote sensing technology}

Japan-based Panasonic in collaboration with Kyoto University developed a new remote-sensing technology to measure vital signs such as heart-rate, heartbeat interval and others.

The new remote-sensing system is a combination of millimetre-wave spread-spectrum radar technology and signal analysis algorithm, which identifies signals from the body.

The technology comprises of high-sensitive spread-spectrum radar and feature-based heartbeat interval estimation algorithm.

^{Vivasure receives CE Mark for bioabsorbable percutaneous vascular closure device}

Irish firm Vivasure Medical received CE Mark approval for its fully bioabsorbable percutaneous vascular closure device developed for use in large-bore femoral arteriotomies.

Based on the company’s patented PerQseal technology platform, the Vivasure closure device is claimed to be the only approved bioabsorbable, sutureless and fully synthetic option to close large arteriotomies, which are a result of percutaneous transcatheter procedures.

An arteriotomy is a puncture hole in a vessel in the groin, which provides access to arteries for catheter-based procedures.